ArticleTropical diseases, travel medicine and vaccines2026
A single polypeptide vaccine derived from multiple antigens confers protection against staphylococcus aureus infection in mice.
Article in Tropical diseases, travel medicine and vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of Methicillin-resistance Staphylococcus aureus (MRSA) has posed a crucial threat in healthcare systems worldwide. Vaccination is ideal prevention against infection from antibiotic-resistance bacteria such as MRSA. Unfortunately, the development of S. aureus vaccine has faced tremendous challenges, suffering from repetitive failure of clinical trials. In this study, we formulated a panel of single polypeptide vaccines Sta-V5*1-3 based on a multi-valent S. aureus vaccine Sta-V5 previously developed by our team. The single polypeptide vaccines composed of antigen fragments induced robust humoral responses and protective immunity against MRSA infection in multiple animal disease models with indistinguishable efficacy when compared with Sta-V5 vaccine. We also attempted to formulate an epitope vaccine Sta-V5-EP based on T cell and B cell epitopes of antigens from Sta-V5. However, Sta-V5-EP failed to elicit sufficient protection in mouse model. Taken together, design of Sta-V5* vaccines represent a valuable S. aureus vaccine platform that avoids the laborious purification of multiple antigens and contamination with impurities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.